Genmab A/S was incorporated on June 11, 1998. They are an international biotechnology company specializing in the treatment of antibodies for cancer and other diseases. Their core purpose is to improve the lives of patients by creating and developing innovative antibody products. The company's vision is to transform cancer treatments and advance its well-differentiated and well-tolerated antibody pipeline by launching its own patented product in 2025. They are building and expanding their late-stage development and commercial capabilities so that they can bring their proprietary products to market in the future. 

GMAB

GMAB Profile